In vitro activity of nanoliposomal amphotericin B against terbinafine-resistant Trichophyton indotineae isolates

The emergence of resistance in dermatophytes underscores the necessity for developing novel and alternative treatment options.

The present study aimed to evaluate the in vitro activity of nanoliposomal amphotericin B against a large panel of terbinafine-resistant Trichophyton indotineae isolates. In vitro susceptibility testing of nanoliposomal amphotericin B and comparators against 50 clinical isolates of terbinafine-resistant T. indotineae strains was performed by broth microdilution according to the Clinical and Laboratory Standards Institute (CLSI) M38-A3 document.

The highest MIC₉₀ and widest MIC range were found for terbinafine (4 and ≥ 4 µg/ml) followed by itraconazole (0.5 and 0.016–16 µg/ml). In contrast, the nanoliposomal amphotericin B and conventional amphotericin B exhibited low MIC₉₀ (0.5 µg/ml) and MIC range (0.25–0.5 µg/ml).

The study findings revealed that nanoliposomal amphotericin B might be a promising candidate against terbinafine-resistant strains of T. indotineae. However, further studies are required to pave the way for developing novel antifungal compounds to combat fungal resistance.